Recombinant Zoster Vaccine Efficacy Appears Durable

Between 5 and 7 years after vaccination, efficacy in participants aged ≥50 was 84%.

Vaccination can markedly lower risk for herpes zoster (HZ), but immunity may decline over time. The recombinant zoster vaccine (RZV; Shingrix) consists of varicella-zoster glycoprotein E combined with the proprietary adjuvant system, AS01B. In two prior placebo-controlled, manufacturer-funded trials (ZOE-50 and ZOE-70), the vaccine exhibited ≥97% efficacy after 3.2 years in those aged ≥50 and almost 90% efficacy after 3.7 years in those aged ≥70. Vaccinated participants were subsequently offered enrollment in an open-label long-term follow-up study for an additional 6 years; this report presents an interim analysis. Because the placebo groups were subsequently vaccinated with RZV, efficacy analyses used age- and region-matched historical co…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Recombinant Zoster Vaccine Efficacy Appears Durable

Topics

Reviewing Author